Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

There’s a new coronavirus subvariant catching the attention of global doctors and researchers: it’s being called “XEC.” ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 8 ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...